Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Diane Ndisebuye

2 papers in the library · 1 citation · publishing 2026

Papers

Cannabis and Psychedelics Among U.S. Young Adults: Use, Messaging Exposure, Perceptions, and Legalization Support

International Journal of Environmental Research and Public Health February 17, 2026 Carla J. Berg, Cassidy R Loparco, Darcey M. Mccready et al. 1 citation

Among 3,227 US adults aged 18–34 surveyed in 2025, past-6-month cannabis use was reported by 40.5% and past-year psychedelic use by 11.9%. Psychedelics had less legalization support, less promotional and risk-message exposure, and lower social acceptability than cannabis, while being perceived as more addictive and harmful. Factors linked to both cannabis and psychedelic use included lower perceived addictiveness and harm, higher social acceptability, more adverse childhood experiences, more promotional and risk-message exposure, and higher scores on a mental health questionnaire. Greater legalization support for both substances was associated with lower perceived addictiveness and harm, higher social acceptability, and more promotional-message exposure. Message exposure may be especially important in shaping psychedelic use and legalization support.

Retail Availability of Intoxicating Cannabis and Mushroom Products Across Eleven U.S. Cities: Sales Persist Despite Prohibitions.

Journal of Studies on Alcohol and Drugs May 28, 2026 Cassidy R Loparco, Matthew E Rossheim, Kayla K Tillett et al.

Retail sales of intoxicating cannabis products (DICPs) like delta-8 THC and hallucinogenic mushrooms are widespread in US smoke shops, including in states where they are explicitly illegal. In a survey of 1,023 smoke shops across eleven states, 51.4% of those that answered reported selling DICPs, with availability ranging from 2.0% in New York City to 93.8% in Jacksonville, FL. Among shops that answered about mushrooms, 59.7% sold them, and over half of those sold Amanita mushrooms. One-third of retailers could not identify the type of mushroom they sold. The authors argue for greater retail surveillance, education, and enforcement.